Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)
|
Common Stock [Member]
Sonnet BioTherapeutics Holdings, Inc. [Member]
|
Additional Paid-in Capital [Member]
Sonnet BioTherapeutics Holdings, Inc. [Member]
|
Additional Paid-in Capital [Member]
RORSCHACH I LLC [Member]
|
Retained Earnings [Member]
Sonnet BioTherapeutics Holdings, Inc. [Member]
|
Retained Earnings [Member]
RORSCHACH I LLC [Member]
|
Parent [Member]
Sonnet BioTherapeutics Holdings, Inc. [Member]
|
| Balance as of June 13, 2025 (inception) at Sep. 30, 2022 |
$ 4
|
$ 88,872,336
|
|
$ (91,411,059)
|
|
$ (2,538,719)
|
| Balance, shares at Sep. 30, 2022 |
31,496
|
|
|
|
|
|
| Sale of common stock, net of issuance costs |
$ 10
|
20,895,948
|
|
|
|
20,895,958
|
| Sale of common stock, net of issuance costs, shares |
104,159
|
|
|
|
|
|
| Net share settlement of warrants |
$ 6
|
(6)
|
|
|
|
|
| Net share settlement of warrants, shares |
64,928
|
|
|
|
|
|
| Issuance of common stock on vesting of restricted stock units and awards |
|
|
|
|
|
|
| Issuance of common stock on vesting of restricted stock units and awards, shares |
954
|
|
|
|
|
|
| Exercise of warrants |
$ 2
|
847
|
|
|
|
849
|
| Exercise of warrants, shares |
17,249
|
|
|
|
|
|
| Share-based compensation |
|
248,626
|
|
|
|
248,626
|
| Net loss |
|
|
|
(18,832,694)
|
|
(18,832,694)
|
| Ending balance, value at Sep. 30, 2023 |
$ 22
|
110,017,751
|
|
(110,243,753)
|
|
(225,980)
|
| Balance, shares at Sep. 30, 2023 |
218,786
|
|
|
|
|
|
| Sale of common stock, net of issuance costs |
$ 16
|
3,916,927
|
|
|
|
3,916,943
|
| Sale of common stock, net of issuance costs, shares |
163,281
|
|
|
|
|
|
| Net share settlement of warrants |
|
|
|
|
|
|
| Net share settlement of warrants, shares |
1,795
|
|
|
|
|
|
| Share-based compensation |
|
50,005
|
|
|
|
50,005
|
| Net loss |
|
|
|
(1,168,509)
|
|
(1,168,509)
|
| Retirement of shares in connection with reverse stock split |
|
|
|
|
|
|
| Retirement of shares in connection with reverse stock split, shares |
(190)
|
|
|
|
|
|
| Ending balance, value at Dec. 31, 2023 |
$ 38
|
113,984,683
|
|
(111,412,262)
|
|
2,572,459
|
| Balance, shares at Dec. 31, 2023 |
383,672
|
|
|
|
|
|
| Balance as of June 13, 2025 (inception) at Sep. 30, 2023 |
$ 22
|
110,017,751
|
|
(110,243,753)
|
|
(225,980)
|
| Balance, shares at Sep. 30, 2023 |
218,786
|
|
|
|
|
|
| Ending balance, value at Jun. 30, 2024 |
$ 67
|
117,170,431
|
|
(114,552,392)
|
|
2,618,106
|
| Balance, shares at Jun. 30, 2024 |
650,284
|
|
|
|
|
|
| Balance as of June 13, 2025 (inception) at Sep. 30, 2023 |
$ 22
|
110,017,751
|
|
(110,243,753)
|
|
(225,980)
|
| Balance, shares at Sep. 30, 2023 |
218,786
|
|
|
|
|
|
| Sale of common stock, net of issuance costs |
$ 17
|
3,976,365
|
|
|
|
3,976,382
|
| Sale of common stock, net of issuance costs, shares |
167,987
|
|
|
|
|
|
| Net share settlement of warrants |
$ 9
|
(9)
|
|
|
|
|
| Net share settlement of warrants, shares |
94,288
|
|
|
|
|
|
| Issuance of common stock on vesting of restricted stock units and awards |
|
|
|
|
|
|
| Issuance of common stock on vesting of restricted stock units and awards, shares |
976
|
|
|
|
|
|
| Share-based compensation |
|
231,190
|
|
|
|
231,190
|
| Net loss |
|
|
|
(7,437,232)
|
|
(7,437,232)
|
| Retirement of shares in connection with reverse stock split |
|
|
|
|
|
|
| Retirement of shares in connection with reverse stock split, shares |
(190)
|
|
|
|
|
|
| Exercise and modification of warrants, net of issuance costs |
$ 17
|
2,969,884
|
|
|
|
2,969,901
|
| Exercise and modification of warrants, net of issuance costs, shares |
168,437
|
|
|
|
|
|
| Ending balance, value at Sep. 30, 2024 |
$ 65
|
117,195,181
|
|
(117,680,985)
|
|
(485,739)
|
| Balance, shares at Sep. 30, 2024 |
650,284
|
|
|
|
|
|
| Balance as of June 13, 2025 (inception) at Dec. 31, 2023 |
$ 38
|
113,984,683
|
|
(111,412,262)
|
|
2,572,459
|
| Balance, shares at Dec. 31, 2023 |
383,672
|
|
|
|
|
|
| Issuance of common stock on vesting of restricted stock units and awards |
|
|
|
|
|
|
| Issuance of common stock on vesting of restricted stock units and awards, shares |
976
|
|
|
|
|
|
| Share-based compensation |
|
60,395
|
|
|
|
60,395
|
| Net loss |
|
|
|
365,425
|
|
365,425
|
| Exercise of warrants |
$ 4
|
55,996
|
|
|
|
56,000
|
| Exercise of warrants, shares |
4,375
|
|
|
|
|
|
| Ending balance, value at Mar. 31, 2024 |
$ 42
|
114,101,074
|
|
(111,046,837)
|
|
3,054,279
|
| Balance, shares at Mar. 31, 2024 |
389,023
|
|
|
|
|
|
| Net share settlement of warrants |
$ 9
|
(9)
|
|
|
|
|
| Net share settlement of warrants, shares |
92,493
|
|
|
|
|
|
| Share-based compensation |
|
60,395
|
|
|
|
60,395
|
| Net loss |
|
|
|
(3,505,555)
|
|
(3,505,555)
|
| Exercise and modification of warrants, net of issuance costs |
$ 16
|
2,946,952
|
|
|
|
2,946,968
|
| Exercise and modification of warrants, net of issuance costs, shares |
164,062
|
|
|
|
|
|
| Sale of common stock |
|
62,019
|
|
|
|
62,019
|
| Sale of common stock, net of issuance costs, shares |
4,706
|
|
|
|
|
|
| Ending balance, value at Jun. 30, 2024 |
$ 67
|
117,170,431
|
|
(114,552,392)
|
|
2,618,106
|
| Balance, shares at Jun. 30, 2024 |
650,284
|
|
|
|
|
|
| Balance as of June 13, 2025 (inception) at Sep. 30, 2024 |
$ 65
|
117,195,181
|
|
(117,680,985)
|
|
(485,739)
|
| Balance, shares at Sep. 30, 2024 |
650,284
|
|
|
|
|
|
| Sale of common stock, net of issuance costs |
$ 105
|
7,622,514
|
|
|
|
7,622,619
|
| Sale of common stock, net of issuance costs, shares |
1,050,500
|
|
|
|
|
|
| Net share settlement of warrants |
|
|
|
|
|
|
| Net share settlement of warrants, shares |
1,209
|
|
|
|
|
|
| Share-based compensation |
|
60,395
|
|
|
|
60,395
|
| Net loss |
|
|
|
(3,160,706)
|
|
(3,160,706)
|
| Retirement of shares in connection with reverse stock split |
|
|
|
|
|
|
| Retirement of shares in connection with reverse stock split, shares |
(373)
|
|
|
|
|
|
| Shares released from abeyance |
$ 3
|
(3)
|
|
|
|
|
| Shares released from abeyance, shares |
32,375
|
|
|
|
|
|
| Exercise of warrants |
$ 127
|
(127)
|
|
|
|
|
| Exercise of warrants, shares |
1,273,436
|
|
|
|
|
|
| Ending balance, value at Dec. 31, 2024 |
$ 300
|
124,877,960
|
|
(120,841,691)
|
|
4,036,569
|
| Balance, shares at Dec. 31, 2024 |
3,007,431
|
|
|
|
|
|
| Balance as of June 13, 2025 (inception) at Sep. 30, 2024 |
$ 65
|
117,195,181
|
|
(117,680,985)
|
|
(485,739)
|
| Balance, shares at Sep. 30, 2024 |
650,284
|
|
|
|
|
|
| Ending balance, value at Jun. 30, 2025 |
$ 333
|
125,061,805
|
|
(128,108,617)
|
$ (596,667)
|
(3,046,479)
|
| Balance, shares at Jun. 30, 2025 |
3,332,728
|
|
|
|
|
|
| Balance as of June 13, 2025 (inception) at Dec. 31, 2024 |
$ 300
|
124,877,960
|
|
(120,841,691)
|
|
4,036,569
|
| Balance, shares at Dec. 31, 2024 |
3,007,431
|
|
|
|
|
|
| Sale of common stock, net of issuance costs |
$ 10
|
116,805
|
|
|
|
116,815
|
| Sale of common stock, net of issuance costs, shares |
98,846
|
|
|
|
|
|
| Issuance of common stock on vesting of restricted stock units and awards |
$ 2
|
(2)
|
|
|
|
|
| Issuance of common stock on vesting of restricted stock units and awards, shares |
17,152
|
|
|
|
|
|
| Net loss |
|
|
|
(3,491,122)
|
|
(3,491,122)
|
| Ending balance, value at Mar. 31, 2025 |
$ 312
|
124,994,763
|
|
(124,332,813)
|
|
662,262
|
| Balance, shares at Mar. 31, 2025 |
3,123,429
|
|
|
|
|
|
| Net loss |
|
|
|
(3,775,804)
|
|
(3,775,804)
|
| Shares released from abeyance |
$ 16
|
(16)
|
|
|
|
|
| Shares released from abeyance, shares |
155,125
|
|
|
|
|
|
| Sale of common stock |
$ 5
|
67,058
|
|
|
|
67,063
|
| Sale of common stock, net of issuance costs, shares |
54,174
|
|
|
|
|
|
| Ending balance, value at Jun. 30, 2025 |
$ 333
|
125,061,805
|
|
(128,108,617)
|
(596,667)
|
(3,046,479)
|
| Balance, shares at Jun. 30, 2025 |
3,332,728
|
|
|
|
|
|
| Balance as of June 13, 2025 (inception) at Jun. 12, 2025 |
|
|
|
|
|
|
| Net loss |
|
|
|
|
(596,667)
|
|
| Ending balance, value at Jun. 30, 2025 |
$ 333
|
$ 125,061,805
|
|
$ (128,108,617)
|
$ (596,667)
|
$ (3,046,479)
|
| Balance, shares at Jun. 30, 2025 |
3,332,728
|
|
|
|
|
|